2021
DOI: 10.1016/j.molstruc.2021.129925
|View full text |Cite
|
Sign up to set email alerts
|

Investigation of the newly characterized baimantuoluoamide a and baimantuoluoamide b alkaloids as potential cyclin-dependent kinase 4 (CDK4) inhibitors using molecular docking and molecular dynamics simulations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 18 publications
(5 citation statements)
references
References 54 publications
0
4
0
Order By: Relevance
“…The maximum number of minimization cycles was set at 5,000, with an energy gradient convergence threshold of 0.001 kJ/mol/Å [37,38] . This extensive MD simulation provided valuable insights into the dynamic behaviour and stability of the TC2/5HT4 complex [39,40,41] …”
Section: Molecular Dynamics (Md) Simulationmentioning
confidence: 99%
See 1 more Smart Citation
“…The maximum number of minimization cycles was set at 5,000, with an energy gradient convergence threshold of 0.001 kJ/mol/Å [37,38] . This extensive MD simulation provided valuable insights into the dynamic behaviour and stability of the TC2/5HT4 complex [39,40,41] …”
Section: Molecular Dynamics (Md) Simulationmentioning
confidence: 99%
“…[37,38] This extensive MD simulation provided valuable insights into the dynamic behaviour and stability of the TC2/5HT4 complex. [39,40,41]…”
Section: Compmentioning
confidence: 99%
“…To bridge the gap in knowledge and complement in vitro and in vivo assays, in silico and computational analyses (or simply molecular docking studies) have become new and important experimental tools to predict molecular interactions between plant metabolites and cellular factors. Using this technology, Gurushankar et al [ 15 ] studied the potential of newly characterised alkaloids baimantuoluoamide A and baimantuoluoamide B (from plant species such as Datura metel L.) as CDK4 inhibitors. CDK4, together with CDK6, is bound and activated by D-type cyclins for the G1-to-S phase transition of the cell cycle [ 16 ].…”
Section: Anticancer Mechanismsmentioning
confidence: 99%
“…p16 and p19 are inhibitors of CDK4/6 [ 16 ]. With respect to baimantuoluoamide B–CDK4 interaction, amino acid residues Phe93, Asp99, and Ile12 were involved, along with Lys35, which is involved in CDK4 inhibition [ 15 ]. Both baimantuoluoamide A and baimantuoluoamide B interact with the non-conserved residues of CDK4 in the ATP binding pocket, which are involved in selective CDK4 inhibition.…”
Section: Anticancer Mechanismsmentioning
confidence: 99%
“…The MM/GBSA method was used to examine the baimantuoluoamide B binding on a per-residue basis and the top donating amino acid residues was found. The findings showed that baimantuoluoamide B is a promising hit molecule that can be used to grow selective CDK4 inhibitors in the future (Gurushankar et al 2021). Based on the theoretical efficacy, analyze their experimental capability for nanoparticle synthesis using D. metel.…”
Section: Introductionmentioning
confidence: 99%